Teleflex Incorporated will host a conference call on May 1, 2025, to discuss its Q1 financial results.
Quiver AI Summary
Teleflex Incorporated will host a conference call on May 1, 2025, at 8:00 a.m. Eastern Time to discuss its first quarter financial results and provide an operational update. Participants can pre-register for the call through a provided link or listen via a live audio webcast on the company's website. An audio replay will be available after the call, accessible by phone or online. Teleflex, a global medical technology provider, focuses on improving health and quality of life through innovative solutions across various therapeutic areas and boasts a portfolio of well-known brands. For further details, contact Lawrence Keusch, Vice President of Investor Relations.
Potential Positives
- Teleflex will provide its first quarter financial results and operational updates, indicating transparency and engagement with stakeholders.
- The conference call demonstrates Teleflex's commitment to communication and investor relations, as they facilitate direct access to company insights.
- Teleflex highlights its diverse portfolio and dedication to improving health outcomes, reinforcing its position as a key player in the medical technology sector.
- The inclusion of trusted brands under the Teleflex umbrella showcases the company's established market presence and reliability in healthcare solutions.
Potential Negatives
- None
FAQ
When is Teleflex's first quarter financial results conference call?
Teleflex will host its conference call on May 1, 2025, at 8:00 a.m. Eastern Time.
How can I participate in the Teleflex conference call?
You can pre-register using the provided link to receive dial-in information or join the live audio webcast on teleflex.com.
What is the conference ID for the Teleflex call?
The conference ID for the Teleflex call is 69028.
Will there be a replay available for the Teleflex conference call?
Yes, an audio replay will be available starting at 11:00 a.m. Eastern Time on May 1, 2025.
What areas does Teleflex focus on in their medical technology solutions?
Teleflex offers solutions in anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TFX Congressional Stock Trading
Members of Congress have traded $TFX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TFX stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 02/25.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$TFX Hedge Fund Activity
We have seen 250 institutional investors add shares of $TFX stock to their portfolio, and 268 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC removed 494,147 shares (-66.4%) from their portfolio in Q4 2024, for an estimated $87,948,283
- POINT72 ASSET MANAGEMENT, L.P. removed 407,442 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $72,516,527
- INVESCO LTD. added 347,003 shares (+48.1%) to their portfolio in Q4 2024, for an estimated $61,759,593
- DIAMOND HILL CAPITAL MANAGEMENT INC added 262,364 shares (+inf%) to their portfolio in Q4 2024, for an estimated $46,695,544
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 261,279 shares (+4.4%) to their portfolio in Q4 2024, for an estimated $46,502,436
- MAGNETAR FINANCIAL LLC added 215,961 shares (+105.2%) to their portfolio in Q4 2024, for an estimated $38,436,738
- CEREDEX VALUE ADVISORS LLC removed 199,975 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $35,591,550
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TFX Analyst Ratings
Wall Street analysts have issued reports on $TFX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 10/31/2024
To track analyst ratings and price targets for $TFX, check out Quiver Quantitative's $TFX forecast page.
$TFX Price Targets
Multiple analysts have issued price targets for $TFX recently. We have seen 3 analysts offer price targets for $TFX in the last 6 months, with a median target of $191.0.
Here are some recent targets:
- Anthony Petrone from Mizuho Securities set a target price of $155.0 on 04/16/2025
- An analyst from Morgan Stanley set a target price of $191.0 on 03/05/2025
Full Release
WAYNE, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 1, 2025.
To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com .
An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com .
Contacts:
Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investors.teleflex.com
610-948-2836
